18F-氟环丁氨酸PET/CT用于高危原发性前列腺癌术前淋巴结分期:前瞻性试验最终结果
该前瞻性单中心研究纳入72例高危原发性前列腺癌患者,评估18F-氟环丁氨酸PET/CT对淋巴结转移的术前诊断性能,以盆腔淋巴结清扫病理为金标准。患者水平分析显示其诊断性能显著(AUC 0.66,p 0.04),敏感度50%、特异度81%;视觉评分≥4为独立预测因子(OR 4.27,p 0.02)。但区域水平半定量参数均未达统计学显著。
要点
- 患者水平18F-氟环丁氨酸PET/CT诊断淋巴结转移AUC 0.66,敏感度50%、特异度81%。
- 视觉评分≥4是淋巴结转移独立预测因子(OR 4.27,p 0.02)。
- 区域水平半定量参数(SUVmax、TBR)诊断性能均无统计学意义。
核心结论
- 在高危原发性前列腺癌中,18F-氟环丁氨酸较11C-胆碱显示一定优势,但检测转移淋巴结的敏感度仍不足以替代盆腔淋巴结清扫。
- 视觉评估(结合形态与功能)较半定量评估更有前景,但主要依赖读片者经验而非明确的淋巴结摄取。
研究设计与样本
- 前瞻性单中心研究,连续纳入活检证实前列腺癌、完成标准分期(含11C-胆碱PET/CT)且适合盆腔淋巴结清扫的患者,行研究性18F-氟环丁氨酸PET/CT,以清扫病理验证。
- 共94例接受18F-氟环丁氨酸PET/CT,最终分析72例高危患者(排除22例:8例局限清扫、3例中危、2例放疗、4例M1、5例新辅助内分泌治疗)。
- 患者水平分析n=72;区域水平分析n=576;共获取1671枚淋巴结。
主要发现
- 组织学确认淋巴结转移18/72例(25%);1671枚淋巴结中45枚(3%)为转移。
- 每例患者切除淋巴结中位数22枚(均值23±10,范围8-51),转移淋巴结中位数2枚(均值3±2,范围1-10);转移淋巴结中位大小5 mm(均值5±2.5,范围2-10)。
- 患者水平:18F-氟环丁氨酸AUC 0.66(p 0.04),敏感度50%、特异度81%、PPV 47%、NPV 83%、准确率74%;11C-胆碱AUC 0.60(p 0.2),敏感度50%、特异度70%、PPV 36%、NPV 81%、准确率65%。
- 多变量分析:Briganti列线图(OR 1.03,p 0.04)和18F-氟环丁氨酸视觉评分≥4(OR 4.27,p 0.02)为淋巴结转移独立预测因子。
- 区域水平半定量参数均无统计学意义:TBR-A 18F-氟环丁氨酸AUC 0.61(p 0.35)vs 胆碱AUC 0.57(p 0.54);TBR-BM 18F-氟环丁氨酸AUC 0.61(p 0.36)vs 胆碱AUC 0.58(p 0.52);淋巴结SUVmax 18F-氟环丁氨酸AUC 0.51(p 0.91)vs 胆碱AUC 0.51(p 0.94)。
关键数值与推荐
- 视觉5分法:1-2分可能阴性,4-5分可能阳性,3分不确定;淋巴结摄取高于周围本底由至少两名对11C-胆碱设盲的读片者判定。
- 半定量指标包括SUVmax及靶本比(TBR),本底分别取主动脉(A)和骨髓(BM)。
- Briganti列线图预测淋巴结转移风险中位数19%。
临床怎么用
- 18F-氟环丁氨酸PET/CT可作为高危原发性前列腺癌术前淋巴结分期的补充手段,但敏感度有限,阴性结果不能替代盆腔淋巴结清扫。
- 判读时应重视视觉评估(结合形态与功能),视觉评分≥4提示淋巴结转移风险升高。
- 半定量参数(SUVmax、TBR)在区域水平未显示显著诊断价值,不宜单独作为决策依据。
局限性
- 单中心前瞻性研究,最终分析样本量72例。
- 18F-氟环丁氨酸诊断性能仅针对淋巴结转移探索,未评估盆腔内或盆腔外M1病灶。
- 视觉评估主要依赖读片者经验,而非明确的淋巴结摄取。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The conventional imaging flowchart for prostate cancer (PCa) staging may fail in correctly detecting lymph node metastases (LNM). Pelvic lymph node dissection (PLND) represents the only reliable method, although invasive. A new amino acid PET compound, [18F]-fluciclovine, was recently authorized in suspected PCa recurrence but not yet included in the standard staging work-up of primary PCa. A prospective monocentric study was designed to evaluate [18F]-fluciclovine PET/CT diagnostic performance for preoperative LN staging in primary high-risk PCa. METHODS: Consecutive patients (pts) with biopsy-proven PCa, standard staging (including [11C]choline PET/CT), eligible for PLND, were enrolled to undergo an investigational [18F]-fluciclovine PET/CT. Nodal uptake higher than surrounding background was reported by at least two readers (blinded to [11C]choline) using a visual 5-point scale (1-2 probably negative; 4-5 probably positive; 3 equivocal); SUVmax, target-to-background (aorta-A; bone marrow-BM) ratios (TBRs), were also calculated. PET results were validated with PLND. [18F]-fluciclovine PET/CT performance using visual score and semi-quantitative indexes was analyzed both per patient and per LN anatomical region, compared to conventional [11C]choline and clinical predictive factors (to note that diagnostic performance of [18F]-fluciclovine was explored for LNM but not examined for intrapelvic or extrapelvic M1 lesions). RESULTS: Overall, 94 pts underwent [18F]-fluciclovine PET/CT; 72/94 (77%) high-risk pts were included in the final analyses (22 pts excluded: 8 limited PLND; 3 intermediate-risk; 2 treated with radiotherapy; 4 found to be M1; 5 neoadjuvant hormonal therapy). Median LNM risk by Briganti nomogram was 19%. LNM confirmed on histology was 25% (18/72 pts). Overall, 1671 LN were retrieved; 45/1671 (3%) LNM detected. Per pt, median no. of removed LN was 22 (mean 23 ± 10; range 8-51), of LNM was 2 (mean 3 ± 2; range 1-10). Median LNM size was 5 mm (mean 5 ± 2.5; range 2-10). On patient-based analyses (n = 72), diagnostic performance for LNM resulted significant with [18F]-fluciclovine (AUC 0.66, p 0.04; 50% sensitivity, 81% specificity, 47% PPV, 83% NPV, 74% accuracy), but not with [11C]choline (AUC 0.60, p 0.2; 50%, 70%, 36%, 81%, and 65% respectively). Briganti nomogram (OR = 1.03, p = 0.04) and [18F]-fluciclovine visual score (≥ 4) (OR = 4.27, p = 0.02) resulted independent predictors of LNM at multivariable analyses. On region-based semi-quantitative analyses (n = 576), PET/CT performed better using TBR parameters (TBR-A similar to TBR-BM; TBR-A fluciclovine AUC 0.61, p 0.35, vs choline AUC 0.57 p 0.54; TBR-BM fluciclovine AUC 0.61, p 0.36, vs choline AUC 0.58, p 0.52) rather than using absolute LN SUVmax (fluciclovine AUC 0.51, p 0.91, vs choline AUC 0.51, p 0.94). However, in all cases, diagnostic performance was not statistically significant for LNM detection, although slightly in favor of the experimental tracer [18F]-fluciclovine for each parameter. On the contrary, visual interpretation significantly outperformed PET semi-quantitative parameters (choline and fluciclovine: AUC 0.65 and 0.64 respectively; p 0.03) and represents an independent predictive factor of LNM with both tracers, in particular [18F]-fluciclovine (OR = 8.70, p 0.002, vs OR = 3.98, p = 0.03). CONCLUSION: In high-risk primary PCa, [18F]-fluciclovine demonstrates some advantages compared with [11C]choline but sensitivity for metastatic LN detection is still inadequate compared to PLND. Visual (combined morphological and functional), compared to semi-quantitative assessment, is promising but relies mainly on readers' experience rather than on unquestionable LN avidity. TRIAL REGISTRATION: EudraCT number: 2014-003,165-15.
引用
- Zanoni L, Bianchi L, Nanni C, et al. [18F]-Fluciclovine PET/CT for preoperative nodal staging in high-risk primary prostate cancer: final results of a prospective trial. Eur J Nucl Med Mol Imaging. 2021. PMID: 34213609. doi:10.1007/s00259-021-05429-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。